Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability

Helen Swede, Thomas E. Rohan, Herbert Yu, Joseph C. Anderson, Richard G. Stevens, Jane Brokaw, Joel Levine, Bruce M. Brenner, Carl D. Malchoff, Valerie B. Duffy, Devon C. Pleau, Daniel W. Rosenberg

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Dysregulation of the insulin-like growth factor (IGF) system, a common consequence of adiposity-induced insulin resistance, may be a key underlying mechanism linking excess body weight with colon cancer. Evidence has been derived from studies of cancer and polyps. Supporting data about aberrant crypt foci (ACF), putative pre-polyp changes, have been generated only from animal studies to date. Methods: We randomly selected 26 patients with sex-specific elevated waist-hip-ratio (WHR) and 26 with normal values from a series of 150 patients seeking routine colonoscopy at the University of Connecticut Health Center. Cross-sectional analyses were performed of ACF number (<5, ≥5) in relation to total IGF1, IGF-binding protein-3 (IGFBP3), insulin, body mass index (BMI), WHR and waist circumference (WC). Visualized ACF in the 20 cm of the distal colon were counted using advanced endoscopic imaging. Results: Patients with ≥5 ACF had higher BMI, WHR, and WC compared with patients with >5 ACF (p = 0.04, p = 0.03, and p = 0.01, respectively). IGFBP3 was reduced (p = 0.02) and IGF1:IGFBP3 molar ratio was greater (p = 0.03) in patients with ≥5 ACF. We did not observe significant associations between ACF number and insulin or total IGF1. Conclusions: Our study provides the first report in humans of a possible association of ACF prevalence and IGF1 bioavailability as characterized by IGF1:IGFBP3 molar ratio and IGFBP3 level. More research is needed to determine whether this relationship is varied by ACF features (e.g., size, dysplasia, molecular changes), synchronous cancer and polyps, and is modified by colon cancer risk factors.

Original languageEnglish (US)
Pages (from-to)653-661
Number of pages9
JournalCancer Causes and Control
Volume20
Issue number5
DOIs
StatePublished - Jul 2009

Fingerprint

Aberrant Crypt Foci
Adiposity
Biological Availability
Polyps
Colonic Neoplasms
Waist-Hip Ratio
Somatomedins
Colonoscopy
Insulin Resistance
Neoplasms
Reference Values
Cross-Sectional Studies
Body Weight
Insulin
Health

Keywords

  • Aberrant crypt foci
  • Adiposity
  • Colon cancer
  • IGF1
  • IGFBP3
  • Insulin resistance
  • Metabolic syndrome
  • Obesity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Swede, H., Rohan, T. E., Yu, H., Anderson, J. C., Stevens, R. G., Brokaw, J., ... Rosenberg, D. W. (2009). Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability. Cancer Causes and Control, 20(5), 653-661. https://doi.org/10.1007/s10552-008-9278-7

Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability. / Swede, Helen; Rohan, Thomas E.; Yu, Herbert; Anderson, Joseph C.; Stevens, Richard G.; Brokaw, Jane; Levine, Joel; Brenner, Bruce M.; Malchoff, Carl D.; Duffy, Valerie B.; Pleau, Devon C.; Rosenberg, Daniel W.

In: Cancer Causes and Control, Vol. 20, No. 5, 07.2009, p. 653-661.

Research output: Contribution to journalArticle

Swede, H, Rohan, TE, Yu, H, Anderson, JC, Stevens, RG, Brokaw, J, Levine, J, Brenner, BM, Malchoff, CD, Duffy, VB, Pleau, DC & Rosenberg, DW 2009, 'Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability', Cancer Causes and Control, vol. 20, no. 5, pp. 653-661. https://doi.org/10.1007/s10552-008-9278-7
Swede, Helen ; Rohan, Thomas E. ; Yu, Herbert ; Anderson, Joseph C. ; Stevens, Richard G. ; Brokaw, Jane ; Levine, Joel ; Brenner, Bruce M. ; Malchoff, Carl D. ; Duffy, Valerie B. ; Pleau, Devon C. ; Rosenberg, Daniel W. / Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability. In: Cancer Causes and Control. 2009 ; Vol. 20, No. 5. pp. 653-661.
@article{3acd4226f38b4437b32fa928819f6085,
title = "Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability",
abstract = "Background: Dysregulation of the insulin-like growth factor (IGF) system, a common consequence of adiposity-induced insulin resistance, may be a key underlying mechanism linking excess body weight with colon cancer. Evidence has been derived from studies of cancer and polyps. Supporting data about aberrant crypt foci (ACF), putative pre-polyp changes, have been generated only from animal studies to date. Methods: We randomly selected 26 patients with sex-specific elevated waist-hip-ratio (WHR) and 26 with normal values from a series of 150 patients seeking routine colonoscopy at the University of Connecticut Health Center. Cross-sectional analyses were performed of ACF number (<5, ≥5) in relation to total IGF1, IGF-binding protein-3 (IGFBP3), insulin, body mass index (BMI), WHR and waist circumference (WC). Visualized ACF in the 20 cm of the distal colon were counted using advanced endoscopic imaging. Results: Patients with ≥5 ACF had higher BMI, WHR, and WC compared with patients with >5 ACF (p = 0.04, p = 0.03, and p = 0.01, respectively). IGFBP3 was reduced (p = 0.02) and IGF1:IGFBP3 molar ratio was greater (p = 0.03) in patients with ≥5 ACF. We did not observe significant associations between ACF number and insulin or total IGF1. Conclusions: Our study provides the first report in humans of a possible association of ACF prevalence and IGF1 bioavailability as characterized by IGF1:IGFBP3 molar ratio and IGFBP3 level. More research is needed to determine whether this relationship is varied by ACF features (e.g., size, dysplasia, molecular changes), synchronous cancer and polyps, and is modified by colon cancer risk factors.",
keywords = "Aberrant crypt foci, Adiposity, Colon cancer, IGF1, IGFBP3, Insulin resistance, Metabolic syndrome, Obesity",
author = "Helen Swede and Rohan, {Thomas E.} and Herbert Yu and Anderson, {Joseph C.} and Stevens, {Richard G.} and Jane Brokaw and Joel Levine and Brenner, {Bruce M.} and Malchoff, {Carl D.} and Duffy, {Valerie B.} and Pleau, {Devon C.} and Rosenberg, {Daniel W.}",
year = "2009",
month = "7",
doi = "10.1007/s10552-008-9278-7",
language = "English (US)",
volume = "20",
pages = "653--661",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability

AU - Swede, Helen

AU - Rohan, Thomas E.

AU - Yu, Herbert

AU - Anderson, Joseph C.

AU - Stevens, Richard G.

AU - Brokaw, Jane

AU - Levine, Joel

AU - Brenner, Bruce M.

AU - Malchoff, Carl D.

AU - Duffy, Valerie B.

AU - Pleau, Devon C.

AU - Rosenberg, Daniel W.

PY - 2009/7

Y1 - 2009/7

N2 - Background: Dysregulation of the insulin-like growth factor (IGF) system, a common consequence of adiposity-induced insulin resistance, may be a key underlying mechanism linking excess body weight with colon cancer. Evidence has been derived from studies of cancer and polyps. Supporting data about aberrant crypt foci (ACF), putative pre-polyp changes, have been generated only from animal studies to date. Methods: We randomly selected 26 patients with sex-specific elevated waist-hip-ratio (WHR) and 26 with normal values from a series of 150 patients seeking routine colonoscopy at the University of Connecticut Health Center. Cross-sectional analyses were performed of ACF number (<5, ≥5) in relation to total IGF1, IGF-binding protein-3 (IGFBP3), insulin, body mass index (BMI), WHR and waist circumference (WC). Visualized ACF in the 20 cm of the distal colon were counted using advanced endoscopic imaging. Results: Patients with ≥5 ACF had higher BMI, WHR, and WC compared with patients with >5 ACF (p = 0.04, p = 0.03, and p = 0.01, respectively). IGFBP3 was reduced (p = 0.02) and IGF1:IGFBP3 molar ratio was greater (p = 0.03) in patients with ≥5 ACF. We did not observe significant associations between ACF number and insulin or total IGF1. Conclusions: Our study provides the first report in humans of a possible association of ACF prevalence and IGF1 bioavailability as characterized by IGF1:IGFBP3 molar ratio and IGFBP3 level. More research is needed to determine whether this relationship is varied by ACF features (e.g., size, dysplasia, molecular changes), synchronous cancer and polyps, and is modified by colon cancer risk factors.

AB - Background: Dysregulation of the insulin-like growth factor (IGF) system, a common consequence of adiposity-induced insulin resistance, may be a key underlying mechanism linking excess body weight with colon cancer. Evidence has been derived from studies of cancer and polyps. Supporting data about aberrant crypt foci (ACF), putative pre-polyp changes, have been generated only from animal studies to date. Methods: We randomly selected 26 patients with sex-specific elevated waist-hip-ratio (WHR) and 26 with normal values from a series of 150 patients seeking routine colonoscopy at the University of Connecticut Health Center. Cross-sectional analyses were performed of ACF number (<5, ≥5) in relation to total IGF1, IGF-binding protein-3 (IGFBP3), insulin, body mass index (BMI), WHR and waist circumference (WC). Visualized ACF in the 20 cm of the distal colon were counted using advanced endoscopic imaging. Results: Patients with ≥5 ACF had higher BMI, WHR, and WC compared with patients with >5 ACF (p = 0.04, p = 0.03, and p = 0.01, respectively). IGFBP3 was reduced (p = 0.02) and IGF1:IGFBP3 molar ratio was greater (p = 0.03) in patients with ≥5 ACF. We did not observe significant associations between ACF number and insulin or total IGF1. Conclusions: Our study provides the first report in humans of a possible association of ACF prevalence and IGF1 bioavailability as characterized by IGF1:IGFBP3 molar ratio and IGFBP3 level. More research is needed to determine whether this relationship is varied by ACF features (e.g., size, dysplasia, molecular changes), synchronous cancer and polyps, and is modified by colon cancer risk factors.

KW - Aberrant crypt foci

KW - Adiposity

KW - Colon cancer

KW - IGF1

KW - IGFBP3

KW - Insulin resistance

KW - Metabolic syndrome

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=67349092910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349092910&partnerID=8YFLogxK

U2 - 10.1007/s10552-008-9278-7

DO - 10.1007/s10552-008-9278-7

M3 - Article

C2 - 19067190

AN - SCOPUS:67349092910

VL - 20

SP - 653

EP - 661

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 5

ER -